title: Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase.
abstract: In contrast to antipsychosis drugs which inhibit the dopamine-activated adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] of caudate nucleus, dopaminergic drugs for treatment of Parkinson's disease stimulate this cyclase. Stimulants and inhibitors of cholinergic neurons inhibited this adenylate cyclase activity competitively and specifically. Thus, the mechanism by which dopaminergic medications ameliorate the effects of Parkinson's disease includes activation of the dopamine-sensitive adenylate cyclase. Excessive activation might be present during the psychotic episodes seen in patients with parkinsonism who are overtreated. The enzymatic effects of the drugs that affect cholinergic mechanisms seem to be generally in keeping with the pharmacological reciprocity between psychoses and extrapyramidal function, except for the anticholinergic ones which inhibited this cyclase although they can be hallucinogenic.
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D002421:Caudate Nucleus / Q000187:drug effects / Q000201:enzymology*; D004298:Dopamine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D007700:Kinetics; D008297:Male; D051379:Mice; D010277:Parasympathomimetics / Q000494:pharmacology*
chemical_list: D010277:Parasympathomimetics; D000262:Adenylyl Cyclases; D004298:Dopamine
references.citation: J Neurochem. 1975 Aug;25(2):143-9
references.pmid: 237983
references.citation: N Engl J Med. 1976 Mar 11;294(11):567-72
references.pmid: 1107835
references.citation: Science. 1975 Jun 20;188(4194):1217-9
references.pmid: 1145194
references.citation: J Med Chem. 1975 Dec;18(12):1194-1200
references.pmid: 1238569
references.citation: Nature. 1974 Apr 12;248(449):596-7
references.pmid: 4150951
references.citation: Proc Natl Acad Sci U S A. 1974 Apr;71(4):1113-7
references.pmid: 4151517
references.citation: Arch Gen Psychiatry. 1974 Jul;31(1):58-61
references.pmid: 4152054
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1974;285(1):71-81
references.pmid: 4280019
references.citation: Proc Natl Acad Sci U S A. 1970 Sep;67(1):305-12
references.pmid: 4318781
references.citation: N Engl J Med. 1972 May 18;286(20):1086-90
references.pmid: 4336251
references.citation: Arch Neurol. 1967 Aug;17(2):124-36
references.pmid: 4382112
references.citation: Dis Nerv Syst. 1968 Dec;29(12):805-16
references.pmid: 4388368
references.citation: Proc Natl Acad Sci U S A. 1972 Aug;69(8):2145-9
references.pmid: 4403305
references.citation: Harvey Lect. 1974;68:115-47
references.pmid: 4452625
references.citation: Proc Natl Acad Sci U S A. 1974 Jul;71(7):2915-8
references.pmid: 4527668
references.citation: Arch Neurol. 1972 Dec;27(6):474-80
references.pmid: 4563448
references.citation: Annu Rev Med. 1971;22:305-26
references.pmid: 4944422
references.citation: Science. 1974 Jun 21;184(4143):1243-53
references.pmid: 17784215